US Senators Introduce INSULIN Act
Analysis based on 6 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026
The proposed INSULIN Act, if passed, would directly impact pharmaceutical companies like Eli Lilly and Company, Sanofi, and Novo Nordisk by potentially regulating insulin prices, which could affect their revenue streams. For the healthcare and insurance industries, it would likely lead to changes in coverage and out-of-pocket costs for millions of Americans, potentially increasing demand for insulin and related supplies due to improved affordability.
A bipartisan group of senators in the United States has introduced the INSULIN Act, a bill aiming to cap the cost of insulin at $35 per month for Americans with private insurance plans and establish a pilot program for uninsured individuals in 10 states. This legislation follows a similar measure in the Inflation Reduction Act that capped insulin costs for Medicare beneficiaries. Major insulin manufacturers, including Eli Lilly and Company, Sanofi, and Novo Nordisk, have already taken steps to reduce insulin costs through various programs. The bill faces legislative hurdles but represents a significant effort to address rising healthcare costs and improve affordability for the 8.1 million people in the United States who rely on insulin.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard